Lectin-Dox

**Lectin-Dox** is an investigational glycan-targeted liposomal doxorubicin formulation developed for pancreatic cancer. It consists of doxorubicin encapsulated in a PEGylated liposome whose surface is modified with the recombinant lectin rBC2LCN. rBC2LCN binds fucosylated cell-surface glycans, including H type-3 glycan motifs enriched on susceptible pancreatic cancer cells, to promote selective tumor-cell binding and uptake; intracellular doxorubicin then produces cytotoxicity through DNA intercalation and topoisomerase II inhibition. In preclinical Capan-1 pancreatic cancer models with high rBC2LCN binding, Lectin-Dox showed greater cellular uptake and a trend toward greater antitumor activity than non-lectin-modified liposomal doxorubicin. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/79/13_Supplement/2152/634295/Abstract-2152-A-novel-glycan-targeting-cancer))